AIM
RIGL icon

Acrospire Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Acrospire Investment Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-160
Closed -$4K – 1129
2017
Q2 		$4K Sell
160
-280
-64% -$7.66K ﹤0.01% 1996
2017
Q1 		$15K Buy
+440
New +$11.2K 0.01% 1745
2016
Q4 		– Sell
-246
Closed -$9K – 2388
2016
Q3 		$9K Sell
246
-10
-4% -$287 0.01% 1732
2016
Q2 		$6K Sell
256
-150
-37% -$3.73K ﹤0.01% 1843
2016
Q1 		$8K Buy
+406
New +$10K 0.01% 1798

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acrospire Investment Management's RIGL Position: Q3 2017 in Review

Acrospire Investment Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2017, closing a stake of 160 shares — an estimated $4K sold.

Acrospire Investment Management first reported a position in RIGL in Q1 2016 and held it in 5 quarters. The position peaked at $15K in Q1 2017. 108 funds tracked by Wall St. Rank hold RIGL as of Q3 2017.

  • Acrospire Investment Management reported no remaining Rigel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 160 Rigel Pharmaceuticals shares in Q3 2017, an estimated $4K.
  • Acrospire Investment Management first reported a position in Rigel Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Rigel Pharmaceuticals position peaked at $15K in Q1 2017.
  • 108 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.